Keywords: Lundbeck, Second-quarter 2010 financial results
Lundbeck reports 30% rise in 2nd-qtr 2010 profit, with sales fueled by Cipralex
Article | 16 August 2010
Danish drugmaker H Lundbeck A/S reported second quarter 2010 revenue of 3.77 billion Danish kroner (672million), an increase of 7% compared to ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
